USSubmitted label - approval not established

LEAFPRO CBDMED OIL T-FS QD 5% (CANNABIDIOL) OIL

This is a locally preserved regulatory record. Source labeling does not by itself prove efficacy for a condition.

Submitted product label. A product label is preserved locally, but approval or current marketing status is not established.

Product data

Locally preserved regulatory fields

Active ingredients: cannabidiol
Route: Not reported
Dosage form: Not reported
Marketing holder: LEAFMED GMBH
Catalog status: Submitted label - approval not established
Source-reported status: Not reported

Linked local records

Related local records

Substance links use source-reported active ingredients. Condition links come from registered study context and are not efficacy claims.

Cannabinoids and active compounds

cannabidiol

Condition reports

epilepsy Chronic Pain Multiple Sclerosis Parkinson Disease Alzheimer Disease Anxiety Disorders Cancer Pain Stress Disorders, Post-Traumatic Opioid-Related Disorders Alcoholism Bipolar Disorder

Regulatory record

Approval, patents and exclusivity

Patent and exclusivity fields are preserved from the regulator. They are not a legal opinion and are separate from clinical development.

0approval records

0source-reported patents

0exclusivity records

Clinical development

Related registered studies

Phases and statuses are source-reported study stages matched by governed token phrases. They do not prove medicine identity, approval or efficacy.

371candidate study links

PHASE1 · PHASE2RECRUITING

Pathophysiological Mechanisms of Cannabidiol in Stress Regulation

DRUG · Cannabidiol

Early Life Adversity · Trauma · Stress

PHASE3RECRUITING

CardiolRxTM in Recurrent Pericarditis (MAVERIC Phase 3) A Randomized, Double-blind, Placebo-controlled Trial

DRUG · CardiolRx

Recurrent Pericarditis

PHASE2RECRUITING

The Differential Effects of THC vs. CBD on Cognition in Persons With MS

DRUG · CBD

Multiple Sclerosis

PHASE2RECRUITING

Cannabinoid Interactions With Central and Peripheral Pain Mechanisms in Osteoarthritis of the Knee

DRUG · Cannabidiol (CBD)

Osteoarthritis, Knee · Osteoarthritis of the Knee

PHASE2COMPLETED

A Phase 2A Study to Investigate the Safety and Preliminary Analgesic Efficacy of Oral Trichomylin® in Male and Female Participants 18 Years of Age and Above With Advanced Cancer and Moderate to Severe Cancer-Related Pain

DRUG · Trichomylin® capsule (5 mg delta-9-tetrahydrocannabinol: 5 mg cannabidiol: 5 mg cannabichromene)

Cancer Pain

PHASE3COMPLETED

A Randomized, Double-Blind, Placebo-Controlled, Multiple-Center, Efficacy and Safety Study of ZYN002 Administered as a Transdermal Gel to Children, Adolescents and Young Adults With Fragile X Syndrome - RECONNECT

DRUG · ZYN002 - transdermal gel

Fragile X Syndrome · Fragile X Syndrome (FXS)

PHASE4NOT_YET_RECRUITING

Source-reported use

Indications in regulatory records

No indication text was reported by the connected sources.

Medicine identity matching

RxNorm candidates

RxNorm normalizes identity; FAERS supplies non-causal post-market signals.

Identity candidate · score 13.99362500495744

RxNorm concept

Matched from: LEAFPRO CBDMED OIL T-FS QD 3% (CANNABIDIOL) OIL

Official RxNorm record

Identity candidate · score 13.142272709048525

fluocinolone acetonide Topical Oil [Derma-Smoothe FS]

Matched from: LEAFPRO CBDMED OIL T-FS QD 5% (CANNABIDIOL) OIL

Official RxNorm record

Identity candidate · score 13.142272709048525

Derma-Smoothe/FS 0.01 % Topical Oil

Matched from: LEAFPRO CBDMED OIL T-FS QD 5% (CANNABIDIOL) OIL

Official RxNorm record

Identity candidate · score 12.756611523071053

cannabidiol Oral Solution

Matched from: cannabidiol

Official RxNorm record

Identity candidate · score 17.154006958007812

CANNABIDIOL OIL

Matched from: LEAFPRO CBDMED OIL FS QP 3% (CANNABIDIOL) OIL

Official RxNorm record

Identity candidate · score 14.622181238446917

RxNorm concept

Matched from: LEAFPRO CBDMED OIL T-FS QD 3% (CANNABIDIOL) OIL

Safety signals

Locally preserved FAERS reports

23,265reports

13,754reported as serious

FAERS/AEMS reports are post-market signals. Counts do not establish causality or incidence and may contain duplicates or reporting bias.

Sources and provenance

Official source snapshots

DailyMed structured labels

a0b9b4eb-1012-a897-e053-2995a90a6bd6 · version 1

Retrieved 22/08/2026, 21:20:19Verify at source

Locally preserved regulatory fields

Related local records

Cannabinoids and active compounds

Condition reports

Approval, patents and exclusivity

Related registered studies

Indications in regulatory records

RxNorm candidates

RxNorm concept

fluocinolone acetonide Topical Oil [Derma-Smoothe FS]

Derma-Smoothe/FS 0.01 % Topical Oil

cannabidiol Oral Solution

CANNABIDIOL OIL

RxNorm concept

Locally preserved FAERS reports

Official source snapshots

DailyMed structured labels

cannabidiol Oral Product

Cannabidiolic acid

CANNABIDIOL 20 mg ORAL CAPSULE, LIQUID FILLED [leafPro CBDmed Softgels T-FS QD 20]

cannabidiol Oral Liquid Product

CANNABIDIOL 5 g in 100 mL ORAL OIL [leafPro CBDmed Oil FS QP 5%]

CANNABIDIOL 20 g in 100 mL ORAL OIL [leafPro CBDmed Oil FS QP 20%]

RxNorm concept

fluocinolone Topical Oil [Derma-Smoothe FS]

CANNABIDIOL 3 g in 100 mL ORAL OIL [leafPro CBDmed Oil FS QP 3%]

CANNABIDIOL 20 g in 100 mL ORAL OIL [leafPro CBDmed Oil T-FS QD 20%]

RxNorm concept

CANNABIDIOL 20 mg ORAL CAPSULE, LIQUID FILLED [leafPro CBDmed Softgels FS QP 20]

CANNABIDIOL 5 g in 100 mL ORAL OIL [leafPro CBDmed Oil T-FS QD 5%]

CANNABIDIOL 3 g in 100 mL ORAL OIL [leafPro CBDmed Oil T-FS QD 3%]